Insider trade

Aldeyra Therapeutics (ALDX): Director bought ~$5.3K

Nancy Miller-rich, Director at Aldeyra Therapeutics, bought ~$5.3K of Aldeyra Therapeutics shares.

~$5.3K
Approx. value · 413 sh @ $12.81: 413
Holds after · shares reported

Traded: May 3, 2021
Filed: Oct 22, 2024

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Aldeyra Therapeutics

For Aldeyra Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALDX page.

Other recent filings by Nancy Miller-rich, Director

SEC Form 4 at Aldeyra Therapeutics (ALDX)Oct 22, 2024

The full history of Nancy Miller-rich, Director is on the profile page.

How this filing works

Explore the data

Other disclosures at Aldeyra Therapeutics

Everything OQRO holds on this company is on its ALDX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data